| Recruiting | Testing the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymp NCT07061951 | National Cancer Institute (NCI) | Phase 2 |
| Recruiting | Anti-CD19/20/22 Chimeric Antigen Receptor T Cells (TriCAR19.20.22 T Cells) for the Treatment of Relapsed or Re NCT07166419 | Ohio State University Comprehensive Cancer Center | Phase 1 |
| Recruiting | Q702 for the Treatment of Patients With Hematologic Malignancies NCT06712810 | Mayo Clinic | Phase 1 |
| Recruiting | Sonrotoclax, Rituximab, and Zanubrutinib in Treating Participants With Chronic Lymphocytic Leukemia, Small Lym NCT06839053 | Fred Hutchinson Cancer Center | Phase 2 |
| Terminated | Genetically Engineered Cells (EGFRt/19-28z/IL-12 CAR T Cells) for the Treatment of Relapsed or Refractory CD19 NCT06343376 | Roswell Park Cancer Institute | Phase 1 |
| Recruiting | B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cycloph NCT06191887 | Mayo Clinic | Phase 1 |
| Recruiting | Acalabrutinib in Combination With Venetoclax for the Treatment of Refractory or Recurrent Chronic Lymphocytic NCT04941716 | Fred Hutchinson Cancer Center | Phase 2 |
| Recruiting | CD19-Directed CAR-T Cell Therapy for the Treatment of Relapsed/Refractory B Cell Malignancies NCT04892277 | Mayo Clinic | Phase 1 |
| Withdrawn | Ipilimumab, Ibrutinib, and Nivolumab for the Treatment of Chronic Lymphocytic Leukemia and Richter Transformat NCT04781855 | M.D. Anderson Cancer Center | Phase 1 |
| Recruiting | Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lym NCT05418088 | Sumithira Vasu | Phase 1 |
| Terminated | Daratumumab and Ibrutinib for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia, DIRECT Stu NCT04230304 | Mayo Clinic | Phase 2 |
| Completed | CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymph NCT04578600 | Joseph Tuscano | Phase 1 |
| Recruiting | Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or NCT04169737 | M.D. Anderson Cancer Center | Phase 2 |
| Terminated | CD19-Specific T Cells Post AlloSCT NCT03579888 | M.D. Anderson Cancer Center | Phase 1 |
| Active Not Recruiting | Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in P NCT04205409 | University of Washington | Phase 2 |
| Active Not Recruiting | Intermittent Duvelisib Dosing in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymp NCT03961672 | City of Hope Medical Center | Phase 2 |
| Terminated | Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial NCT03878524 | OHSU Knight Cancer Institute | Phase 1 |
| Withdrawn | Rivogenlecleucel Donor Lymphocyte Immunotherapy in Treating Patients With Recurrent Blood Cancers After Stem C NCT03807063 | Fred Hutchinson Cancer Center | Phase 1 |
| Active Not Recruiting | Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphom NCT04007029 | Jonsson Comprehensive Cancer Center | Phase 1 |
| Withdrawn | Modified Immune Cells (CD19-CD22 CAR T Cells) in Treating Patients With Recurrent or Refractory CD19 Positive, NCT04029038 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Active Not Recruiting | Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma NCT03479268 | City of Hope Medical Center | Phase 1 |
| Active Not Recruiting | A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Exp NCT03277729 | Fred Hutchinson Cancer Center | Phase 1 / Phase 2 |
| Completed | Venetoclax and Ibrutinib in Patients With Relapsed/Refractory CLL or SLL NCT03045328 | Steven E. Coutre | Phase 2 |
| Terminated | Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelate NCT03246906 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Metformin Hydrochloride and Ritonavir in Treating Patients With Relapsed or Refractory Multiple Myeloma or Chr NCT02948283 | City of Hope Medical Center | Phase 1 |
| Completed | Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocy NCT03010358 | Alexey Danilov, MD | Phase 1 / Phase 2 |
| Completed | Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell Transplant NCT02869633 | Vanderbilt-Ingram Cancer Center | Phase 2 |
| Active Not Recruiting | Venetoclax and Ibrutinib in Treating Patients With Chronic or Small Lymphocytic Leukemia NCT02756897 | M.D. Anderson Cancer Center | Phase 2 |
| Terminated | Lenalidomide and Obinutuzumab in Treating Patients With Recurrent or Refractory Chronic Lymphocytic Leukemia o NCT02225275 | M.D. Anderson Cancer Center | Phase 2 |
| Withdrawn | Ibrutinib or Idelalisib in Treating Patients With Persistent or Relapsed Chronic Lymphocytic Leukemia, Small L NCT02662296 | Fred Hutchinson Cancer Center | Phase 2 |
| Terminated | Mechanisms of Idelalisib-Associated Diarrhea in Patients With Relapsed Chronic Lymphocytic Leukemia, Indolent NCT02928510 | Jonsson Comprehensive Cancer Center | — |
| Terminated | Buparlisib and Ofatumumab or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Le NCT02614508 | Emory University | Phase 1 |
| Completed | Ex Vivo-activated Autologous Lymph Node Lymphocytes in Treating Patients With Chronic Lymphocytic Leukemia NCT02530515 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Adoptive Immunotherapy in Relapsed Hematological Malignancy: Early GVHD Prophylaxis NCT02593123 | Virginia Commonwealth University | Phase 2 |
| Terminated | Lenalidomide and AT-101 in Treating Patients With Relapsed B-Cell Chronic Lymphocytic Leukemia NCT01003769 | Mayo Clinic | Phase 1 / Phase 2 |
| Completed | Nivolumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or High-Risk Untreated Chronic Lymphoc NCT02420912 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic L NCT02332980 | Mayo Clinic | Phase 2 |
| Active Not Recruiting | Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chron NCT02153580 | City of Hope Medical Center | Phase 1 |
| Active Not Recruiting | Lenalidomide, Ibrutinib, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Le NCT02160015 | National Cancer Institute (NCI) | Phase 1 |
| Active Not Recruiting | Ibrutinib With or Without Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia NCT02007044 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Laboratory Treated T Cells in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Non- NCT01865617 | Fred Hutchinson Cancer Center | Phase 1 / Phase 2 |
| Completed | Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Tran NCT01822509 | National Cancer Institute (NCI) | Phase 1 |
| Unknown | NK Cells in Cord Blood Transplantation NCT01619761 | M.D. Anderson Cancer Center | Phase 1 |
| Completed | Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Sm NCT01886859 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Donor Atorvastatin Treatment in Preventing Severe Acute GVHD After Nonmyeloablative Peripheral Blood Stem Cell NCT01527045 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfun NCT01638533 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patient NCT01251575 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated NCT01231412 | Fred Hutchinson Cancer Center | Phase 3 |
| Completed | Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients NCT01008462 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation, and Donor Bone Marrow Transplant Followed by NCT00789776 | Fred Hutchinson Cancer Center | Phase 1 / Phase 2 |
| Completed | Vorinostat, Cladribine, and Rituximab in Treating Patients With Mantle Cell Lymphoma, Relapsed Chronic Lymphoc NCT00764517 | OHSU Knight Cancer Institute | Phase 2 |
| Completed | Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer NCT00723099 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Fludarabine Phosphate and Total-Body Irradiation Before Donor Peripheral Blood Stem Cell Transplant in Treatin NCT00060424 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Autologous Stem Cell Transplant Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or R NCT00005803 | Fred Hutchinson Cancer Center | Phase 1 / Phase 2 |